Literature DB >> 24419641

Pancytopenia secondary to cytomegalovirus reactivation.

Justin Ruey Tse1, Gan Xon Ng.   

Abstract

A 64-year-old woman with a 1-year history of microscopic polyangiitis developed isolated pancytopenia secondary to cytomegalovirus (CMV) reactivation. The patient was originally admitted to the medical service for the management of a rapidly progressing 10 cm ulcer on her left lower extremity. Prior to admission, the patient had been on several immunosuppressive agents for the treatment of microscopic polyangiitis, including prednisone, azathioprine, cyclophosphamide and rituximab. Her hospital course was notable for pancytopenia and after a very thorough diagnostic work-up, the aetiology was found to be secondary to CMV reactivation. This was confirmed by blood analysis that revealed a highly elevated CMV level at 899 100 copies/mL by quantitative PCR. The patient was promptly treated with intravenous ganciclovir for a total course of 14 days before transitioning to an oral regimen. She had a pronounced response to the anti-CMV therapy with complete recovery of her white cell count, haemoglobin and platelet count to baseline.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24419641      PMCID: PMC3902496          DOI: 10.1136/bcr-2013-201857

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

Review 1.  Cytomegalovirus: disease syndromes and treatment.

Authors:  W L Drew; J P Lalezari
Journal:  Curr Clin Top Infect Dis       Date:  1999

2.  Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors.

Authors:  Yasumi Furui; Masahiro Satake; Yuji Hoshi; Shigeharu Uchida; Ko Suzuki; Kenji Tadokoro
Journal:  Transfusion       Date:  2013-08-22       Impact factor: 3.157

3.  Fatal cytomegalovirus infection in two patients with systemic lupus erythematosus undergoing intensive immunosuppressive therapy: role for cytomegalovirus vigilance and prophylaxis?

Authors:  Kam Hon Yoon; Kok Yong Fong; Paul Ananth Tambyah
Journal:  J Clin Rheumatol       Date:  2002-08       Impact factor: 3.517

4.  Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.

Authors:  Phillip Scheinberg; Steven H Fischer; Li Li; Olga Nunez; Colin O Wu; Elaine M Sloand; Jeffrey I Cohen; Neal S Young; A John Barrett
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

5.  Interstitial pneumonia due to cytomegalovirus following low-dose methotrexate treatment for rheumatoid arthritis.

Authors:  F Aglas; F Rainer; J Hermann; J Gretler; E Hüttl; W Domej; G J Krejs
Journal:  Arthritis Rheum       Date:  1995-02

6.  Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.

Authors:  B D Pryor; S G Bologna; L E Kahl
Journal:  Arthritis Rheum       Date:  1996-09

7.  Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population.

Authors:  Y Takizawa; S Inokuma; Y Tanaka; K Saito; T Atsumi; M Hirakata; H Kameda; S Hirohata; H Kondo; S Kumagai; Y Tanaka
Journal:  Rheumatology (Oxford)       Date:  2008-06-24       Impact factor: 7.580

  7 in total
  1 in total

1.  Cytomegalovirus and disseminated histoplasmosis-related hemophagocytic lymphohistiocytosis syndrome in an HIV-patient late presenter with IRIS: a case report.

Authors:  Luz A González-Hernández; Monserrat Alvarez-Zavala; Rodolfo I Cabrera-Silva; Pedro Martínez-Ayala; Fernando Amador-Lara; Aída S Ramírez-González; Ana L Ron-Magaña; Vida V Ruiz Herrera; Karina Sánchez-Reyes; Jaime F Andrade-Villanueva
Journal:  AIDS Res Ther       Date:  2020-08-14       Impact factor: 2.250

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.